Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Convatec False /oidc-signin/en-us/

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

30 July 2021

Download press release

PDF Download

 

Strong growth & continued strategic progress

table

 

 (1) All adjusted measures are reconciled to the most directly comparable measure prepared in accordance with IFRS (see Non-IFRS financial information section).

(2) Constant currency growth is calculated by applying the prior period average exchange rates to the Group's actual performance in the respective period.

(3) Adjusted EBIT is equivalent to adjusted operating profit and reported EBIT is equivalent to statutory operating profit.

(4) Organic growth presents period over period growth at constant currency, excluding acquisitions and disposals.

(5) Items referred to as reported measures are equivalent to statutory measures.

 

H1 2021 key highlights:

  • Strong revenue growth ahead of our expectations: +7.4% organic4 growth, +7.0% on a constant currency2 and +11.0% on a reported basis
    • H1 2021 performance was driven by particularly strong growth in Advanced Wound Care, against the weak COVID-depressed comparative, coupled with good growth in Infusion Care and solid performances in Continence & Critical Care and Ostomy Care
  • Continued progress with our transformation by executing on our FISBE (Focus, Innovate, Simplify, Build, Execute) strategy:
    • Strengthened Continence Care with acquisition of Cure Medical
    • Launched innovative and differentiated extended wear infusion set
    • Establishing Marketing and Quality Centres of Excellence
  • Reported operating profit of $136m, 19.9% higher year on year, with adjusted EBIT of $204m, 17.0% higher on a constant currency basis, reflecting the strong revenue growth together with gross margin improvement and beneficial opex phasing.
  • Reported Free Cash Flow (‘FCF’) of $106m (H1 2020: $145m) with adjusted FCF1 of $114m (H1 2020: $148m). Adjusted cash conversion1 of 56.6% (H1 2020: 72.9%) primarily reflecting working capital movements during the period and increased capital investment.
  • Strong balance sheet: leverage of 2.0x Net Debt/Adjusted EBITDA1 (H1 2020: 2.2x; FY 2020: 2.0x).
  • Interim dividend of 1.717 cents declared, in line with prior year.
  • 2021 full year outlook is updated: organic4 revenue growth of between 3.5-5% (previously: 3-4.5%) and a constant currency adjusted EBIT margin of 18-19% (previously: 18-19.5%).  Based on current FX this would equate to guidance of between 17.1-18.1% for the published adjusted EBIT margin.   


Karim Bitar, Chief Executive Officer, commented:

“I am pleased with our continued strategic progress, on delivering another semester of good growth and on the underlying performance of the Group, notwithstanding that the financial performance was helped by the COVID impacted Q2 comparative. Our ongoing strategic transformation remains on track, and we have made progress during the period.      

“Whilst we are mindful of relatively tougher comparatives in the second half and the continuing COVID uncertainty, particularly in Asia Pacific and Latin America, we are updating our full year organic revenue growth expectations. Our constant currency margin guidance has been tightened against a backdrop of higher than anticipated cost inflation and a planned increase in transformation investments, primarily in R&D and sales and marketing, given our confidence in our strategy.

“We will continue to strengthen our foundations as we pivot to sustainable and profitable growth, and I am confident in the inherent attractiveness of the markets we serve and in Convatec’s growth prospects.”

 (...)

Download the full text of this announcement

PDF Download

 

Analysts and Investors

ir@convatec.com

Kate Postans: VP of IR & Corporate Communications  

+44 (0)7826 447807

   

Media

 

Buchanan: Charles Ryland / Chris Lane / Vicky Haynes 

+44 (0)207 466 5000

 

Press Release

See all

3/5/2022

Annual Results for the twelve months ended 31 December 2020

Read more

3/31/2021

Convatec awarded contract for Ostomy Products from Vizient, Inc.

Read more

4/29/2021

Trading update for the three months ended 31 March 2021

Read more

6/21/2021

Global commercial rights signed by Convatec Ltd for ChloraSolv, innovative wound debrider from RLS

Read more

7/30/2021

Interim Results for the six months ended 30 June 2021

Read more

9/30/2021

Convatec Group Plc Announces Offering of $500 Million Senior Notes due 2029

Read more

10/1/2021

Convatec Group Plc Announces Pricing of $500 Million 3.875% Senior Notes due 2029

Read more

5/13/2022

Trading update for the three months ended 30 September 2021

Read more

5/13/2022

Convatec awarded contract for Advanced Wound Care Products from Vizient, Inc.

Read more

5/13/2022

25 years of AQUACEL

Read more

5/13/2022

Chief Financial Officer succession

Read more